Synovus Financial Corp cut its holdings in AstraZeneca (NYSE:AZN) by 43.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,319 shares of the company’s stock after selling 4,098 shares during the quarter. Synovus Financial Corp’s holdings in AstraZeneca were worth $186,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of AZN. Atria Investments LLC raised its position in AstraZeneca by 26.3% in the fourth quarter. Atria Investments LLC now owns 33,495 shares of the company’s stock worth $1,162,000 after acquiring an additional 6,979 shares in the last quarter. Bank of Montreal Can raised its position in AstraZeneca by 243.4% in the fourth quarter. Bank of Montreal Can now owns 415,126 shares of the company’s stock worth $14,404,000 after acquiring an additional 294,246 shares in the last quarter. Naples Global Advisors LLC raised its position in AstraZeneca by 6.2% in the fourth quarter. Naples Global Advisors LLC now owns 30,133 shares of the company’s stock worth $1,046,000 after acquiring an additional 1,752 shares in the last quarter. Ingalls & Snyder LLC bought a new stake in AstraZeneca in the fourth quarter worth about $865,000. Finally, Fisher Asset Management LLC raised its position in AstraZeneca by 2.7% in the fourth quarter. Fisher Asset Management LLC now owns 11,917,332 shares of the company’s stock worth $413,531,000 after acquiring an additional 315,759 shares in the last quarter. Hedge funds and other institutional investors own 15.18% of the company’s stock.
Get AstraZeneca alerts:
AstraZeneca opened at $36.33 on Friday, according to Marketbeat.com. The company has a debt-to-equity ratio of 0.93, a quick ratio of 0.62 and a current ratio of 0.80. The stock has a market cap of $92.30 billion, a price-to-earnings ratio of 8.51, a P/E/G ratio of 1.94 and a beta of 0.61. AstraZeneca has a 1 year low of $28.43 and a 1 year high of $36.75.
AstraZeneca (NYSE:AZN) last posted its quarterly earnings data on Friday, May 18th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.28 by $0.20. The firm had revenue of $5.18 billion for the quarter, compared to the consensus estimate of $5.24 billion. AstraZeneca had a return on equity of 34.74% and a net margin of 13.36%. The business’s revenue for the quarter was down 4.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.99 EPS. sell-side analysts expect that AstraZeneca will post 1.7 earnings per share for the current year.
Several equities research analysts have commented on AZN shares. Zacks Investment Research upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Monday, January 22nd. BMO Capital Markets set a $40.00 price target on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Thursday, March 22nd. ValuEngine upgraded shares of AstraZeneca from a “buy” rating to a “strong-buy” rating in a research report on Monday, March 19th. Sanford C. Bernstein boosted their price target on shares of AstraZeneca from $40.00 to $42.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. Finally, Jefferies Group upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating and boosted their price target for the stock from $28.43 to $36.70 in a research report on Monday, March 19th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $38.12.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca (NYSE:AZN).